mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis, Membranous
Conditions
Glomerulonephritis, Membranous
Trial Timeline
May 1, 2002 → —
NCT ID
NCT00135967About mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9
mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 is a phase 2/3 stage product being developed by Roche for Glomerulonephritis, Membranous. The current trial status is completed. This product is registered under clinical trial identifier NCT00135967. Target conditions include Glomerulonephritis, Membranous.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00135967 | Phase 2/3 | Completed |
Competing Products
8 competing products in Glomerulonephritis, Membranous
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| infusion of ADR-001 (Mesenchymal stem cell) | Rohto Pharmaceutical | Phase 1 | 33 |
| Iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin | Pfizer | Phase 2 | 51 |
| Ramipril | Sanofi | Phase 3 | 76 |
| MOR202 | Biogen | Phase 1/2 | 38 |
| MOR202 | Biogen | Phase 2 | 49 |